TICKERNERD
Menu
ARWRARWRHealthcare · Biotechnology

ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$62
+3.58% on the day

The 15 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. hold a median 12-month price target of $107 — +72.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 4 Nov 2026 — in the upper half.

Market cap
$8.4B
Ticker Nerd rank
54/ 100
Median analyst target
$107
Analysts covering
15
Revenue$75.3M+171.0% y/y
Operating income−$170.1M
Net income−$178.9M
Free cash flow−$181.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.4%
1M
−3.9%
YTD
−7.1%
1Y
+62.9%
From 52W high
−31.2%
From 52W low
+62.9%
$38
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARWR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arrowhead Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
54/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Value
91
Accruals
75
Momentum
73
Volatility
44
Revisions
39
Growth
37
Size
17
Issuance
12

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ARWR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARWR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100$120$140Jan 26Apr 26Jul 26Oct 26ARWRHigh $126Median $107Low $74

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
14 Buy1 Hold0 Sell
Low $74Median $107High $126

The green dot is the last close — the median target sits +72.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
15 Oct 2026Chardan CapitalMaintainsBuy$115
15 Oct 2026HC Wainwright & Co.ReiteratesBuy$120
15 Oct 2026UBSAssumesBuy$63 → $109
24 Sept 2026Goldman SachsReinstatesNeutral$74
8 Sept 2026CitigroupInitiatesBuy—
8 Sept 2026CitigroupInitiatesBuy$108
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$120
1 Sept 2026HC Wainwright & Co.ReiteratesBuy—
31 Aug 2026Chardan CapitalMaintainsBuy$115
31 Aug 2026Chardan CapitalMaintainsBuy—
31 Aug 2026RBC CapitalReiteratesOutperform—
31 Aug 2026RBC CapitalReiteratesOutperform$100
6 Aug 2026HC Wainwright & Co.MaintainsBuy—
6 Aug 2026HC Wainwright & Co.MaintainsBuy$115 → $120
30 July 2026B. Riley SecuritiesMaintainsBuy—
30 July 2026B. Riley SecuritiesMaintainsBuy$101 → $123
27 July 2026HC Wainwright & Co.MaintainsBuy—
27 July 2026HC Wainwright & Co.MaintainsBuy$100 → $115
23 July 2026Morgan StanleyMaintainsOverweight$100 → $120
23 July 2026Morgan StanleyMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ARWR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ARWR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Arrowhead Pharmaceuticals, Inc. returned +62.9% against +14.8% for the S&P 500, dividends included.

ARWR vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26ARWRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARWR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
6
Fundamentals

Arrowhead Pharmaceuticals, Inc. (ARWR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
47.1×

Cheaper than 15% of US stocks

Price / sales
12.6×

Cheaper than 11% of US stocks

Price / book
18.2×

Cheaper than 5% of US stocks

EV / EBITDA
−40.9×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
171.0%

Higher than 95% of US stocks

Earnings growth (YoY)
171.0%

Higher than 89% of US stocks

Gross margin
—
Operating margin
−226.0%

Higher than 10% of US stocks

Net margin
−47.8%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−55.2%

Higher than 20% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arrowhead Pharmaceuticals, Inc. (ARWR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arrowhead Pharmaceuticals, Inc. has a market value of $8.4B and an enterprise value of $8.2B.

  • Revenue in the twelve months to 30 June 2026: $669.5M. The latest quarter grew 171.0% year on year.

  • Net income over the same four quarters: −$272.1M, a −40.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$75.1M.

  • Shares outstanding: 141.1M.

  • Trailing P/E: 47.1×; forward P/E: −12.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Arrowhead Pharmaceuticals, Inc. employs 711 people — $942K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Nov 2026

Data provided by Twelve Data

Peers

ARWR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARWRArrowhead Pharmaceuticals, Inc.$8.4B54
CORTCorcept Therapeutics, Inc.$8.5B72
CYTKCytokinetics, Inc.$8.8B44
SYRESpyre Therapeutics, Inc.$9.1B34
PTGXProtagonist Therapeutics, Inc.$9.1B97
MDGLMadrigal Pharmaceuticals, Inc.$9.2B80
KRYSKrystal Biotech, Inc.$9.2B88

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arrowhead Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARWR news & analysis

Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity

Business Wire · 4 Nov 2026positive

Arrowhead Pharmaceuticals completed a refinancing with funds managed by Sixth Street. It retired its existing $400 million facility at a $68 million discount to the contractual minimum repayment amount and announced a new $400 million facility.

Why it matters — The company said the transaction lowers borrowing costs, improves near-term liquidity, extends debt maturity, and increases financial and operational flexibility.

Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results

Business Wire · 3 Nov 2026neutral

Arrowhead Pharmaceuticals announced it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss financial results for the fiscal year ended September 30, 2026. A live audio webcast will be available on the company’s Investors website, with a replay expected approximately two hours later.

Why it matters — The event provides ARWR watchers with a scheduled opportunity to hear the company discuss its fiscal-year financial results.

Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026

Business Wire · 2 Nov 2026neutral

Arrowhead Pharmaceuticals announced that it will present data at the American Heart Association Scientific Sessions in Chicago. The oral presentation is scheduled for November 7 during a session on novel lipid-lowering therapies and is titled “First-in-Human Trial of a Dual Functional RNAi Mo.”

Why it matters — The presentation gives ARWR watchers a scheduled opportunity to hear clinical data from a first-in-human trial.

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Business Wire · 27 Oct 2026positive

Arrowhead Pharmaceuticals announced that adults with familial chylomicronaemia syndrome in England and Wales will have NHS access to REDEMPLO (plozasiran), a newly licensed treatment option to reduce triglycerides when diet and conventional therapies have not provided an adequate response.

Why it matters — The announcement describes expanded treatment access for a condition addressed by an Arrowhead product.

Arrowhead Pharmaceuticals: ARO-MAPT Results Unlock A New Platform

Seeking Alpha · 15 Oct 2026positive

Arrowhead reported ARO-MAPT phase 1 results with up to 85% CSF tau reduction, which the source describes as validating its subcutaneous CNS siRNA platform. The company plans two ARO-MAPT phase 2 trials and four additional CNS candidates entering the clinic by the end of 2027.

Why it matters — The results and planned CNS pipeline expansion are relevant to ARWR watchers tracking the development of the company’s CNS platform.

FAQ

Frequently asked questions about ARWR stock

What is the ARWR stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. have a median 12-month price target of $107, with estimates ranging from $74 to $126. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARWR stock a buy right now?

Of the 15 analysts covering Arrowhead Pharmaceuticals, Inc., 14 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrowhead Pharmaceuticals, Inc. 54 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARWR?

As at 4 Nov 2026, Arrowhead Pharmaceuticals, Inc. ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will ARWR stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +72.7% from the last close, and Ticker Nerd's factor model ranks Arrowhead Pharmaceuticals, Inc. 54 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARWR stock forecast for 2030?

No analyst covering Arrowhead Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARWR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $74 to $126 over the next 12 months.

How has ARWR stock performed over the past year?

Arrowhead Pharmaceuticals, Inc. returned +62.9% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins.

What is the latest news on ARWR?

The most recent item we track (Business Wire, 4 Nov 2026): "Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity". Arrowhead Pharmaceuticals completed a refinancing with funds managed by Sixth Street. It retired its existing $400 million facility at a $68 million discount to the contractual minimum repayment amount and announced a new $400 million facility.

Company

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company that develops medicines for intractable diseases using RNA interference, a gene-silencing approach designed to reduce the production of disease-causing proteins. Arrowhead Pharmaceuticals focuses on therapeutic areas including cardiometabolic, liver, pulmonary, neuromuscular, complement-mediated, and central nervous system disorders. Its portfolio includes both commercial and clinical-stage programs built around its targeted RNAi platform, which is designed for tissue-specific delivery and precise gene suppression. The company works across product development, clinical research, and commercialization, with a pipeline that includes multiple investigational therapies aimed at genetically driven diseases. Arrowhead Pharmaceuticals serves the broader healthcare market by advancing treatments for complex conditions with limited options, positioning itself as a specialized player in RNA-based drug development.

CEO Dr. Christopher R. Anzalone Ph.D. · 711 employees · United States · https://arrowheadpharma.com